A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-15

Study Completion Date

2019-07-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase Ia/Ib, open-label, multicenter study will evaluate the safety, tolerability, and preliminary efficacy of DCLL9718S as a single agent (Phase Ia, Arm A) in participants with relapsed or refractory AML or in combination with azacitidine (Phase Ib, Arm B) in participants with previously untreated AML who are not eligible for intensive induction chemotherapy. Each arm will consist of two stages: a dose-escalation stage and an expansion stage. The dose-escalation stage is designed to establish the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for DCLL9718S alone (Arm A) or in combination with azacitidine (Arm B). The dose-expansion stage is designed to characterize the long-term safety and tolerability of DCLL9718S.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

NCT02351037

Acute Myeloid Leukemia (AML)

TERMINATED PHASE2

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

NCT00497991

Myeloid Leukemia

COMPLETED PHASE1

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

NCT02954653

Acute Myeloid Leukemia

TERMINATED PHASE1

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

NCT00358644

Acute Myeloid Leukemia

COMPLETED PHASE2

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

NCT00512083

Leukemia, Myeloid

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: DCLL9718S

Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.

Group Type EXPERIMENTAL

DCLL9718S

Intervention Type DRUG

DCLL9718S will be administered as per the schedule specified in the respective arm.

Arm B: DCLL9718S and Azacitidine

Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m\^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m\^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.

Group Type EXPERIMENTAL

DCLL9718S

Intervention Type DRUG

DCLL9718S will be administered as per the schedule specified in the respective arm.

Azacitidine

Intervention Type DRUG

Azacitidine will be administered as per the schedule specified in the respective arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DCLL9718S

DCLL9718S will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Azacitidine

Azacitidine will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vidaza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
* Adequate end-organ function
* Willing and able to undergo a pre-treatment bone marrow aspirate and biopsy and subsequent bone marrow aspirates and biopsies during treatment

Specifically for participants in Arm A:

* Age greater than or equal to (\>/=) 18 years
* Relapsed or refractory acute myeloid leukemia
* Participants cannot have received more than two prior regimens

Specifically for participants in Arm B:

* Treatment-naive participants with AML who are \>/=75 years old
* Treatment-naive participants unfit for induction chemotherapy for AML due to comorbidities who are \>/=65 years old

Exclusion Criteria

* Diagnosis of acute promyelocytc leukemia
* Prior allogeneic stem cell transplant or solid organ transplant
* Active central nervous system (CNS) involvement by leukemia
* History of idiopathic pulmonary fibrosis, organizing pneumonitis (for example \[e.g.\], bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis
* Treatment with investigational therapy within 14 days prior to Cycle 1, Day 1
* Treatment with a monoclonal antibody within 30 days prior to Cycle 1, Day 1
* Positive for hepatitis C virus (HCV) antibody at screening
* Active hepatitis B virus (HBV) infection
* Known positivity for human immunodeficiency virus (HIV)
* History of other malignancy within 2 years prior to screening
* Family history of long QT syndrome, with a QTc interval greater than (\>) 480 millisecond (msec) at screening, or taking concurrent medications known to prolong QT/QTc interval

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No